Anticancer medicines in development: Assessment of bioactivity profiles within the National Cancer Institute anticancer screening data

Molecular Cancer Therapeutics

Volumn 6, Issue 8, 2007, Pages 2261-2270

  Covell, David G ^a   Huang, Ruili ^a   Wallqvist, Anders ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER SCREENING; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; DRUG ACTIVITY; DRUG SCREENING; HEALTH CARE ORGANIZATION; KIDNEY CANCER; LEUKEMIA; MELANOMA; NEUROBLASTOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); ROC CURVE; UNITED STATES;

EID: 34548091013     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0787     Document Type: Article

References (39)

1. Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28-40.
2. Jacoby E, Schuffenhauer A, Popov M, et al. Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection. Curr Top Med Chem 2005;5:397-411.
3. Orry AJ, Abagyan RA, Cavasotto CN. Structure-based development of target-specific compound libraries. Drug Discov Today 2006;11:261-6.
4. Fischer HP. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery. Biotechnol Annu Rev 2005;11:1-68.
5. Caldwell GW, Yan Z. Screening for reactive intermediates and toxicity assessment in drug discovery. Curr Opin Drug Discov Devel 2006;9:47-60.
6. Brown N, Zehender H, Azzaoui K, Schuffenhauer A, Mayr LM, Jacoby E. A chemoinformatics analysis of hit lists obtained from high-throughput affinity-selection screening. J Biomol Screen 2006;11:123-30.
7. Prasanna MD, Vondrasek J, Wlodawer A, Rodriguez H, Bhat TN. Chemical compound navigator: a web-based chem-BLAST, chemical taxonomy-based search engine for browsing compounds. Proteins 2006;63:907-17.
8. Haber C, Boillat M, van der Schoot B. Precise nanoliter fluid handling system with integrated high-speed flow sensor. Assay Drug Dev Technol 2005;3:203-12.
9. Giuliano KA, Cheung WS, Curran DP, et al. Systems cell biology knowledge created from high content screening. Assay Drug Dev Technol 2005;3:501-14.
10. Perlman ZE, Mitchison TJ, Mayer TU. High-content screening and profiling of drug activity in an automated centrosome-duplication assay. Chembiochem 2005;6:145-51.
11. Blower PE, Cross KP. Decision tree methods in pharmaceutical research. Curr Top Med Chem 2006;6:31-9.
12. Hrusovsky K. Getting on the critical path: better evaluation tools for drug discovery and development. Drug Discov Today 2006;11:773-4.
13. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 1995;34:91-109.
14. Shoemaker RH, Monks A, Alley MC, et al. Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res 1988;276:265-86.
15. Shoemaker RH, Scudiero DA, Melillo G, et al. Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr Top Med Chem 2002;2:229-46.
16. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92.
17. Voeller DM, Grem JL, Pommier Y, Paull K, Allegra CJ. Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. Cancer Chemother Pharmacol 2000;45:409-16.
18. Kohlhagen G, Paull KD, Cushman M, Nagafuji P, Pommier Y. Protein-linked DNA strand breaks induced by NSC314622, a novel noncamptothecin topoisomerase I poison. Mol Pharmacol 1998;54:50-8.
19. Rabow AA, Shoemaker RH, Sausville EA, Covell DG. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J Med Chem 2002;45:818-40.
20. Huang R, Wallqvist A, Covell DG. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action. Biochem Pharmacol 2005;69:1009-39.
21. Huang Y, Blower PE, Yang C, et al. Correlating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1. Pharmacogenomics J 2005;5:112-25.
22. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
23. Bussey KJ, Chin K, Lababidi S, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 2006;5:853-67.
24. Covell DG, Wallqvist A, Huang R, Thanki N, Rabow AA, Lu XJ. Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases. Proteins 2005;59:403-33.
25. Wallqvist A, Huang R, Thanki N, Covell DG. Evaluating chemical structure similarity as an indicator of cellular growth inhibition. J Chem Inf Model 2006;46:430-7.
26. Huang R, Wallqvist A, Thanki N, Covell DG. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action. Pharmacogenomics J 2005;5:381-99.
27. Wallqvist A, Huang R, Covell DG, Roschke AV, Gelhaus KS, Kirsch IR. Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells. Mol Cancer Ther 2005;4:1559-68.
28. Willett P. Similarity-based approaches to virtual screening. Biochem Soc Trans 2003;31:603-6.
29. Martin YC, Kofron JL, Traphagen LM. Do structurally similar molecules have similar biological activity? J Med Chem 2002;45:4350-8.
30. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-35.
31. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
32. Ikediobi ON, Davies H, Bignell G, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5:2606-12.
33. Daylight. Daylight Chemical Information Systems, Inc. Aliso Viejo, CA.
34. Lasko TA, Bhagwat JG, Zou KH, Ohno-Machado L. The use of receiver operating characteristic curves in biomedical informatics. J Biomed Inform 2005;38:404-15.
35. Stephan C, Wesseling S, Schink T, Jung K. Comparison of eight computer programs for receiver-operating characteristic analysis. Clin Chem 2003;49:433-9.
36. Shi LM, Fan Y, Myers TG, et al. Mining the NCI anticancer drug discovery databases: genetic function approximation for the QSAR study of anticancer ellipticine analogues. J Chem Inf Comput Sci 1998;38:189-99.
37. Blower PE, Yang C, Fligner MA, et al. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J 2002;2:259-71.
38. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62.
39. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-22.